Trial Profile
Efficacy of Brentuximab Vedotin treatment in patients with relapsed refractory Hodgkin lymphoma post autologous stem-cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 03 Dec 2018 New trial record